A Phase 2 interventional study of Nab-paclitaxel and Gemcitabine in Pancreatic Adenocarcinoma and Metastatic, sponsored by Theriva Biologics SL. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Theriva Biologics SL · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 415 studies in Neoplasm Metastasis with a site in Spain — 79 open to participants now, 144 under way, 43 of them phase 3. Neoplasm Metastasis · Spain.
Among the 415 studies in Neoplasm Metastasis with a site in Spain, this one is the 240th largest by enrollment of the 393 interventional ones that give a count, is one of 22 that started in 2023, is one of 102 in phase 2, and was the 328th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →79 of the 415 studies in Neoplasm Metastasis with a site in Spain are open now. Recruiting first, the newest first:
Fundacion Miguel Servet · Sites in Spain
Ages 18+
Fernando Gómez Muñoz · Sites in Spain
Ages 18+
Theriva Biologics SL · Sites in Spain
Ages 18+
AstraZeneca · Sites in Spain, United States, France and 6 more countries
Ages 18–130
Immuneering Corporation · Sites in Spain, United States, Australia and 6 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
415 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 159 · Phase 2 179 · Phase 3 112 · Phase 4 7
First in 1996; this study’s year is marked. 22 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 163 across the 393 interventional studies, 454 across the 20 observational. Of the 255 that completed or were terminated, 136 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
329 of 415 have an industry lead sponsor. The 10 most frequent:
Theriva Biologics SL is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Theriva Biologics SL has 4 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
39 of the studies in Neoplasm Metastasis with a site in Spain that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT07221734Phase 3mAbxience Research S.L.Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | 2027-04 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06103864Phase 3AstraZenecaA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | 2027-07-28 |
Add all 39 to your calendar (.ics) → With an account.
Among the 415 studies in Neoplasm Metastasis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
Multi-center, open label, randomized, 2-parallel arm, phase IIb study of nab-paclitaxel and gemcitabine as Standard of Care (SoC) plus/minus VCN-01 in patients with metastatic pancreatic cancer. Gemcitabine and nab-paclitaxel are chemotherapy drugs approved by the FDA to treat pancreatic cancer. VCN-01 is a genetically modified adenovirus characterized by the presence of four independent genetic modifications in the backbone of the wild-type human adenovirus serotype 5 (HAd5) genome that confer tumor selective replication and antitumor activity. Approximately 92 patients in sites in North America and European Union (EU) will be recruited and randomized in a 1:1 ratio to one of two treatment arms (i.e., approximately 46 patients per treatment arm):
A Data Monitoring Committee (DMC) will be convened at regular intervals to assess safety and to look at OS to determine if the trial can continue.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate baseline organ function (hematologic, liver, renal and nutritional)verified by laboratory analyses performed within 72 hours prior to dosing*:
Hematology:
Coagulation (*except in patients on anticoagulants):
Hepatic:
Renal:
Nutritional:
Exclusion Criteria:
<!-- -->
Active infection or other serious illness or disease at the moment of randomization. Active infection includes tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), Virus (HBV; positive HBV surface antigen [HBsAg] result), Virus (HCV; positive HCV Ribonucleic acid [RNA]), or (positive HIV 1/2 antibodies). HBV carriers (patients positive for HBsAg) or those patients requiring antiviral therapy treatment for HBV virus or HCV are not eligible to participate.
However, the following patients are eligible to participate in the study:
o Patients with past or resolved TB are eligible;
o Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible. Blood HBV DNA must be obtained and must be negative in these patients prior to treatment;
o Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nab-paclitaxel and gemcitabine as SoC.
Drug: Nab-paclitaxel · Drug: Gemcitabine
A maximum of two (2) doses of VCN-01 administrated as a single IV infusion in combination with nab-paclitaxel and gemcitabine as SoC.
Drug: Nab-paclitaxel · Drug: Gemcitabine · Genetic: VCN-01
Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.
Overall Survival
From date of randomization until the date of death from any cause, assessed up to 27 months
Time frame: From date of randomization until the date of death from any cause, assessed up to 27 months
Number of TEAEs in Each Treatment Arm
Safety and tolerability of VCN-01, IV administered at Week 1 and Week 14 in Arm 2 measured as incidence of Adverse Events as assessed by CTCAE v5.0
Time frame: until the end of treatment period phase
Time to Progression (TTP) or Progression Free Survival (PFS)
This outcome measure evaluates two related endpoints: Time to Progression (TTP) and Progression-Free Survival (PFS). TTP is defined as the time from randomization to the date of first documented disease progression and assessed up to 27 months. PFS is defined as the time from randomization to the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 27 months.
Time frame: TTP: From randomization until documented disease progression assessed up to 27 months. PFS: From randomization to either progression or death from any cause assessed up to 27 months.
Overall Response Rate (ORR)
Objective response rate (ORR) defined as the sum of patients who achieved partial response (PR) plus patients who achieved complete response (CR) using RECIST version 1.1 criteria.
Time frame: From randomization to partial response or complete response up to 27 months
Disease Control Rate (DCR)
Disease Control Rate (DCR) defined as: stable disease (SD) + partial response (PR) + complete response (CR)
Time frame: From randomization to partial response or complete response up to 27 months
Landmark 1-year Survival
Number of alive participants that were live at the 12-month follow-up period from first enrollment. This measures does not consider the censored patients that had not reached the one-year-Follow-up yet.
Time frame: From randomization to 1-year landmark
Number of Patients With PFS at the 1-year Landmark
Number of patients that have progression free survival at the 1-year landmark (n)
Time frame: From randomization up to 12 months
Duration of Response (DoR)
Duration of Response (DoR) is defined as the time from the date of first documented objective response (Complete Response \[CR\] or Partial Response \[PR\]) to the date of first documented disease progression, or death from any cause, whichever occurs first. This analysis will only include patients who achieved a confirmed objective response.
Time frame: From randomization to disease progression assessed up to 27 months
Neutralizing Anti-VCN-01 Antibodies (Anti-Ad-Nabs)
Determination of neutralizing anti-VCN-01 antibodies (Anti-Ad-Nabs) in serum of Arm 2 patients at different time-points during the study. Cycle 1 (VCN-01+SoC dosing): Pre-dose, day 8 after first VCN-01 dose, day 8 after second VCN-01 dose.
Time frame: From randomization up to 27 months
PH20 Levels in Serum
Determination of PH20 levels in serum of Arm 2 (VCN-01 + SoC) patients at the following time-points: Cycle 1 (VCN-01+SoC dosing): Pre-dose on day 1, 48h post-dose and on day 8; Cycle 2 (SoC dosing): Day 1; Cycle 3 (SoC dosing): Day 1; Cycle 4 (VCN-01+SoC dosing): Pre-dose on day, 48h post-dose and on day 8; On Day 1 of any subsequent SoC cycle.
Time frame: From pre-dose to end of treatment defined as 1 month after the last dose of nab-paclitaxel/gemcitabine.
VCN-01 Genomes Levels in Blood
Determination of VCN-01 genomes in whole blood of Arm 2 (VCN-01 + SoC) patients at the following time-points: Cycle 1 (VCN-01+SoC dosing): Pre-dose and 4h post-dose on day 1, 48h post-dose, on day 8 and day 15; Cycle 2 (SoC dosing): Day 1; Cycle 3 (SoC dosing): Day 1; Cycle 4 (VCN-01+SoC dosing): Pre-dose and 4h post dose on day 1, 48h post-dose, on day 8 and day 15; On Day 1 of any subsequent SoC cycle.
Time frame: From randomization to 27 months
From Dec 20, 2022 through Sep 17, 2024, 171 patients were screened across 17 sites in the US and EU (Spain). 112 participants were randomly allocated to ARM 1-SoC (n=55) or ARM 2-VCN-01+SoC (n=57) in a 1:1 ratio based on the stratification factors ECOG (0 or 1) and geographic region.
| Milestone | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Started | 55 | 57 |
| Completed | 48 | 53 |
| Not completed | 7 | 4 |
| Withdrew: Withdrawal by subject | 7 | 4 |
From date of randomization until the date of death from any cause, assessed up to 27 months
| months | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Overall Survival | 8.6 (6.9 to 11.6) | 10.8 (7.4 to 15.8) |
Safety and tolerability of VCN-01, IV administered at Week 1 and Week 14 in Arm 2 measured as incidence of Adverse Events as assessed by CTCAE v5.0
| number of TEAEs in each treatment arm | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Number of TEAEs in Each Treatment Arm | 299 | 399 |
This outcome measure evaluates two related endpoints: Time to Progression (TTP) and Progression-Free Survival (PFS). TTP is defined as the time from randomization to the date of first documented disease progression and assessed up to 27 months. PFS is defined as the time from randomization to the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 27 months.
| months | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Time to Progression (TTP) or Progression Free Survival (PFS) | 4.6 (3.5 to 6.5) | 7.0 (4.8 to 11.2) |
Objective response rate (ORR) defined as the sum of patients who achieved partial response (PR) plus patients who achieved complete response (CR) using RECIST version 1.1 criteria.
| number participants with PR+CR | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Overall Response Rate (ORR) | 15 | 19 |
Disease Control Rate (DCR) defined as: stable disease (SD) + partial response (PR) + complete response (CR)
| number of participants with PR+CR+SD | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Disease Control Rate (DCR) | 34 | 37 |
Number of alive participants that were live at the 12-month follow-up period from first enrollment. This measures does not consider the censored patients that had not reached the one-year-Follow-up yet.
| number of patients alive | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Landmark 1-year Survival | 10 | 13 |
Number of patients that have progression free survival at the 1-year landmark (n)
| Participants | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Number of Patients With PFS at the 1-year Landmark | 10 | 13 |
Duration of Response (DoR) is defined as the time from the date of first documented objective response (Complete Response \[CR\] or Partial Response \[PR\]) to the date of first documented disease progression, or death from any cause, whichever occurs first. This analysis will only include patients who achieved a confirmed objective response.
| months | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Duration of Response (DoR) | 5.4 (1.9 to 6.8) | 11.2 (7.4 to NA) |
Determination of neutralizing anti-VCN-01 antibodies (Anti-Ad-Nabs) in serum of Arm 2 patients at different time-points during the study. Cycle 1 (VCN-01+SoC dosing): Pre-dose, day 8 after first VCN-01 dose, day 8 after second VCN-01 dose.
| titer | Arm 2 -VCN-01 + SoC |
|---|---|
| Pre-dose | 273.1 ± 466.4 |
| day 8 after first VCN-01 dose | 84390 ± 131174 |
| day 8 after second VCN-01 dose | 18459 ± 18511 |
Determination of PH20 levels in serum of Arm 2 (VCN-01 + SoC) patients at the following time-points: Cycle 1 (VCN-01+SoC dosing): Pre-dose on day 1, 48h post-dose and on day 8; Cycle 2 (SoC dosing): Day 1; Cycle 3 (SoC dosing): Day 1; Cycle 4 (VCN-01+SoC dosing): Pre-dose on day, 48h post-dose and on day 8; On Day 1 of any subsequent SoC cycle.
No measurements were reported for this outcome.
Determination of VCN-01 genomes in whole blood of Arm 2 (VCN-01 + SoC) patients at the following time-points: Cycle 1 (VCN-01+SoC dosing): Pre-dose and 4h post-dose on day 1, 48h post-dose, on day 8 and day 15; Cycle 2 (SoC dosing): Day 1; Cycle 3 (SoC dosing): Day 1; Cycle 4 (VCN-01+SoC dosing): Pre-dose and 4h post dose on day 1, 48h post-dose, on day 8 and day 15; On Day 1 of any subsequent SoC cycle.
| viral particles/ml | Arm 2 -VCN-01 + SoC |
|---|---|
| Pre-dose | 1 ± 0 |
| 4h after first VCN-01 dose | 94545434 ± 270506109 |
| 4h after second VCN-01 dose | 128747533 ± 231157542 |
Collected over All-cause mortality monitored/assessed up to 27 months. Adverse events monitored/assessed from randomization through completion of treatment phase, an average of 1 year. No further adverse events were recorded, unless they were considered related to VCN-01, in accordance with the protocol.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1-SoC | 35/48 (72.9%) | 23/48 (47.9%) | 48/48 (100%) |
| Arm 2 -VCN-01 + SoC | 32/53 (60.4%) | 30/53 (56.6%) | 52/53 (98.1%) |
| Event | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Influenza like illnessGeneral disorders | 0/48 | 7/53 |
| Abdominal PainGastrointestinal disorders | 1/48 | 4/53 |
| PyrexiaGeneral disorders | 2/48 | 3/53 |
| CholangitisHepatobiliary disorders | 2/48 | 2/53 |
| Cholangitis acuteHepatobiliary disorders | 2/48 | 2/53 |
| Drug-induced liver injuryHepatobiliary disorders | 0/48 | 2/53 |
| PneumoniaInfections and infestations | 0/48 | 2/53 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 1/48 | 2/53 |
| Transaminases increasedInvestigations | 0/48 | 2/53 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/48 | 0/53 |
| Event | Arm 1-SoC | Arm 2 -VCN-01 + SoC |
|---|---|---|
| Asthenia /FatigueGeneral disorders | 36/48 | 48/53 |
| PyrexiaGeneral disorders | 12/48 | 41/53 |
| NauseaGastrointestinal disorders | 13/48 | 32/53 |
| Neurotoxicity/Neuropathy peripheralNervous system disorders | 21/48 | 31/53 |
| Anaemia / Iron deficiencyBlood and lymphatic system disorders | 23/48 | 28/53 |
| NeutropeniaBlood and lymphatic system disorders | 18/48 | 27/53 |
| DiarrhoeaGastrointestinal disorders | 22/48 | 27/53 |
| Transaminases increased /ALT increased/AST increasedInvestigations | 10/48 | 27/53 |
| Decreased appetiteMetabolism and nutrition disorders | 20/48 | 27/53 |
| Abdominal PainGastrointestinal disorders | 13/48 | 26/53 |
A total of 55 participants were allocated to ARM Standard of Care (SoC) but only 48 participants received the any dose of the study therapy. A total of 57 participants were allocated to ARM VCN-01 + Standard of Care but only 53 participants received any dose of the study therapy.
| Age, Continuous(years) | Control ARM Standard of Care (SoC) | Experimental ARM VCN-01 + Standard of Care (SoC) | Total |
|---|---|---|---|
| Median | 68.5 (52 to 85) | 66.0 (41 to 86) | 67.6 (41 to 86) |
| Sex: Female, Male(Participants) | Control ARM Standard of Care (SoC) | Experimental ARM VCN-01 + Standard of Care (SoC) | Total |
|---|---|---|---|
| Female | 26 | 27 | 53 |
| Male | 22 | 26 | 48 |
| Race (NIH/OMB)(Participants) | Control ARM Standard of Care (SoC) | Experimental ARM VCN-01 + Standard of Care (SoC) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 44 | 50 | 94 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(Participants) | Control ARM Standard of Care (SoC) | Experimental ARM VCN-01 + Standard of Care (SoC) | Total |
|---|---|---|---|
| United States | 7 | 9 | 16 |
| Spain | 41 | 44 | 85 |
| ECOG(Participants) | Control ARM Standard of Care (SoC) | Experimental ARM VCN-01 + Standard of Care (SoC) | Total |
|---|---|---|---|
| ECOG 0 | 17 | 21 | 38 |
| ECOG 1 | 31 | 32 | 63 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2023 to primary completion in Mar 2025, 26 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion.
Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 26 months is below that.
Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Theriva Biologics SL